Nuvation Bio (Nuvation Bio) Float Percentage Of Total Shares Outstanding : N/A (As of Apr. 27, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Nuvation Bio Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nuvation Bio's float shares is 0.00 Mil. Nuvation Bio's total shares outstanding is 0.00 Mil. Nuvation Bio's float percentage of total shares outstanding is N/A.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nuvation Bio's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nuvation Bio's Institutional Ownership is 0.00%.

Nuvation Bio Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Nuvation Bio's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.00	/	0.00
	=	N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company. The company is engaged in developing therapeutic candidates for the unmet needs in oncology. The firm operates in pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates as treatments for cancer patients.